Not a good buy right now for an impatient investor: no proprietary buy signals, weak/indecisive technicals, and a sharply negative analyst reset (PT cut to $2).
Risk/reward skews unfavorable near $7: limited near-term catalysts and high single-asset execution risk dominate the setup.
Pattern-based odds provided: modest edge for the next month (+5.8%), but near-term bias is not supportive (next week -1.02%), which is unfavorable for an impatient entry.
Positive Catalysts
MACD remains marginally above zero, leaving room for a short-term rebound if buyers defend 6.71 support.
Model-based similar-pattern projection shows potential for a stronger 1-month move (+5.8%) if sentiment/catalysts improve.
No notable hedge fund or insider selling pressure flagged recently (both neutral).
Neutral/Negative Catalysts
is a major sentiment overhang.
Financial Performance
Latest quarter: 2025/Q3.
Revenue: 0 (no operating revenue; unchanged YoY in practical terms).
Net income: -25.625M (losses, though improved YoY per provided data).
EPS: -3.01 (still deeply negative, improved YoY).
Takeaway: financial profile remains development-stage/expense-driven with continued sizable losses; the investment case depends more on pipeline execution/partnering than current fundamentals.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Most recent notable change: 2025-11-25 Wedbush downgraded to Underperform from Neutral and cut PT to $2 (from $23) while assuming coverage.
Stated Wall Street-style bear case (cons): high development costs, single-asset/single-indication dependence, limited catalysts, and competitive alternatives perceived as equal/better.
Pros case (conditional): shares become more compelling if the company lands a development partner or shifts focus to a new indication—but those are not currently evidenced in the provided data.
Wall Street analysts forecast IMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMA is 16 USD with a low forecast of 2 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
Wall Street analysts forecast IMA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IMA is 16 USD with a low forecast of 2 USD and a high forecast of 30 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
2 Buy
0 Hold
1 Sell
Moderate Buy
Current: 7.010
Low
2
Averages
16
High
30
Current: 7.010
Low
2
Averages
16
High
30
Wedbush
Martin Fan
Neutral -> Underperform
downgrade
$23 -> $2
AI Analysis
2025-11-25
Reason
Wedbush
Martin Fan
Price Target
$23 -> $2
AI Analysis
2025-11-25
downgrade
Neutral -> Underperform
Reason
Wedbush analyst Martin Fan downgraded ImageneBio to Underperform from Neutral with a price target of $2, down from $23, while assuming coverage of the stock. The firm recommends investors avoid ImageneBio shares unless the company either gains a development partner, or shifts its focus to a new indication, citing high development costs, the company's reliance on a single asset and indication, a limited catalyst calendar, and what it views as competitors with equivalent or superior product profiles.
Leerink
Outperform
initiated
$30
2025-10-24
Reason
Leerink
Price Target
$30
2025-10-24
initiated
Outperform
Reason
Leerink initiated coverage of ImageneBio (IMA) with an Outperform rating and $30 price target. The firm views shares as "dramatically undervalued," particularly following a selloff in the wake of disappointing competitor Sanofy's (SNY) amlitelimab results on September 4. Leerink believes ImageneBio's lead asset IMG-007, a non-depleting anti-OX40 monoclonal antibody, is a potential blockbuster for atopic dermatitis. Early clinical data for IMG-007 suggests compelling efficacy at Week 16 compared to Dupixent. Competing drug candidate Phase 3 disappointments from Amgen's (AMGN) OX40 rocatinlimab and Sanofi's OX40L amlitelimab have dampened investor sentiment toward the OX40-OX40L class. This yields a favorable setup for IMG-007 to deliver a superior "trifecta" competitive profile, the firm argues.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for IMA
